Press release
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at
About this update from Incyte Corporation
[{"type":"text","content":" WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.\n\n\n\"We look forward to sharing data from our oncology portfolio with the scientific community at this year’s ESMO Congress,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Presentations, including results from studies of retifanlimab and capmatinib, focused on patients with endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer, showcase our continued efforts to pursue innovative therapies for patients with cancer.”\n\n\nKey abstracts from Incyte-sponsored and partner programs include:\n\n\nPoster Presentations\n\n\nImmuno-oncology (IO)\n\n\nRetifanlimab in Patients with Recurrent Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Endometrial Cancer: Final Results from the POD1UM-101 Study (Cohort H) (Abstract #755P. Topic: Gynecological Cancers. Sunday, October 22, 6:00 a.m. – 7:00 a.m. ET)\n\n\nUpdated Results from POD1UM-201: A Phase 2 Study of Retifanlimab in Patients with Advanced or Metastatic Merkel Cell Carcinoma (MCC) (Abstract #1146P. Topic: Melanoma and Other Skin Tumors. Sunday, October 22, 6:00 a.m. – 7:00 a.m. ET)\n\n\nCapmatinib\n\n\nEfficacy of Capmatinib Compared to Standard of Care for German Patients with Locally Advanced or Metastatic NSCLC Harboring METex14 Mutations: Results from the RECAP Study1 (Abstract #1383P. Topic: NSCLC, Metastatic. Monday, October 23, 6:00 a.m. – 7:00 a.m. ET)\n\n\nCapmatinib vs Docetaxel as Second- or Third-line (2/3L) Therapy in Patients (Pts) with METex14-Mutated Advanced NSCLC (aNSCLC): The GeoMETry-3 Trial1 (Abstract #1391P. Topic: NSCLC, Metastatic. Monday, October 23, 6:00 a.m. – 7:00 a.m. ET)\n\n\nFor full session details and data presentation listings, please see the ESMO Congress 2023 (https://www.esmo.org/meeting-calendar/esmo-congress-2023/programme) online program.\n\n\nAbout Zynyz™ (retifanlimab-dlwr)\n\n\nZynyz (retifanlimab-dlwr), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on...